Important factors associated with using kratom among the U. S. population aged 12 years and above in 2019
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20242416Keywords:
Abuse, Annual survey, Kratam, NSDUH, United StatesAbstract
Background: The psychoactive Southeast Asian herb known botanically as Mitragyna speciosa, or Kratom, has recently gained appeal as an illicit drug across the world. Demographic factors may explain the increased use of Kratom. Many demographic characteristics and risk factors are associated with kratom use and mental health. This analytical inquiry used the 2019 NSDUH database to identify and investigate the factors linked with Kratom misuse in the United States.
Methods: This cross-sectional study monitored the 2019 National Survey on Drug Use and Health (NSDUH) dataset, involving a multistage representative area probability sampling method. The data was collected from the non-institutionalized U.S. population aged 12 and above, comprising 98% of the study group. The study used a sample size of 56,136, filtered on inclusion/exclusion criteria. The study findings would offer valuable insights for epidemiologists, policymakers, and the wider community to improve behavioural health.
Results: The study found that 66.45% of Kratom users were unmarried, with 33.555% being married, widowed, or divorced. The low p-value of 0.0001 suggested a link between Kratom consumption and marital status. Individuals without mental health education used Kratom at a higher rate (78%), but no significant relationship was found. Males consumed Kratom at a higher rate (58.76%), while females consumed 41.24%.
Conclusions: The study highlighted the impact of demographic factors like age, marital status, gender, income, and mental health education on Kratom consumption, with implications for public health policy.
Metrics
References
Hasin DS, Grant BF. The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol. 2015;50 (11):1609-40.
Sharma V, Cottler LB, Bares CB, Lopez-Quintero C. Kratom Use Among U.S. Adolescents: Analyses of the 2019 National Survey on Drug Use and Health. J Adolesc Health. 2022;70 (4):677-81.
Maruyama T, Kawamura M, Hanajiri R et al. The botanical origin of kratom (Mitragyna speciosa; Rubiaceae) available as abused drugs in the Japanese markets. J Nat Med. 2009;63 (3):340-4.
Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019;24 (5):874-85.
Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011;7 (3):227-31.
Commissioner O of the. FDA and Kratom. FDA. 2024. Available at www.fda.gov/news-events/public-health-focus/fda-and-kratom. Accessed on 20 December 2023.
Shah K, Tankersley W, Mekala H. Kratom: An Emerging Issue and Need for Regulations in the United States. Prim Care Companion CNS Disord. 2021;23(1):2770.
Prevete E, Kuypers KPC, Theunissen EL, Corazza O, Bersani G, Ramaekers JG. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Hum Psychopharmacol. 2022;37(1):2805.
Palamar JJ. Past-Year Kratom use in the U.S.: estimates from a nationally representative sample. Am J Prev Med. 2021;61(2):240-5.
Kratom: Unsafe and ineffective - Mayo Clinic. 2024. Available at mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/kratom/art-20402171. Accessed on 20 December 2023.
NSDUH. National Survey of Drug Use and Health (NSDUH) Releases. 2021. Available at samhsa.gov/data/release/eases. Accessed on 20 December 2023.
Adzrago D, Obekpa EO, Suragh TA, et al. Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic. Drug Alcohol Depend. 2022;239:109605.
Rogers JM, Smith KE, Strickland JC, Epstein DH. Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample. Front Pharmacol. 2021;12:789075.
Kerridge BT, Pickering RP, Saha TD, Ruan WJ, Chou SP, Zhang H et al. Prevalence, sociodemographic correlates and DSM-5 substance use disorders and other psychiatric disorders among sexual minorities in the United States. Drug Alcohol Depend. 2017;170:82-92.
Umberson D, Crosnoe R, Reczek C. Social Relationships and Health Behavior Across Life Course. Annu Rev Sociol. 2010;36:139-57.
Su Bohnert KM, Ilgen MA, Louzon S, McCarthy JF, Katz IR. Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration. Addiction. 2017;112(7):1193-201.
Dhuffar MK, Griffiths MD. Barriers to female sex addiction treatment in the UK. J Behav Addict. 2018;5(4):562-7.
Kreek MJ. Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Ann N Y Acad Sci. 2011;1231:65-72.
Wakeman SE, Rich JD. Barriers to Medications for Addiction Treatment: How Stigma Kills. Subst Use Misuse. 2018;53(2):330-3.
Pashchenko O, Bromberg DJ, Dumchev K. Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial. PLOS Glob Public Health. 2022;2(11):344.
Matthews S, Dwyer R, Snoek A. Stigma and Self-Stigma in Addiction. J Bioethical Inq. 2017;14(2):275-86.
Schimmel J, Amioka E, Rockhill K. Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Addict Abingdon Engl. 2021;116(1):176-81.
Foley L, Maddison R, Olds T. Self-report use-of-time tools for the assessment of physical activity and sedentary behaviour in young people: systematic review. Obes Rev Off J Int Assoc Study Obes. 2012;13(8):711-22.
Downloads
Published
How to Cite
Issue
Section
